Glaukos (GKOS) Could Be 1% Undervalued After Its Pipeline Growth Narrative
Glaukos (GKOS) has drawn fresh investor attention after its stock closed at $155.39, capping a strong run over the past month and past 3 months without a single defining headline driving the move.
See our latest analysis for Glaukos.
Glaukos has seen momentum build, with a 30 day share price return of 21.85% and a year to date share price return of 40.34%, alongside a 1 year total shareholder return of 56.96% and 5 year total shareholder return of 210.78%.
If Glaukos's recent run has you rethinking where growth in healthcare could come from next, it may be worth scanning for other specialists through the 39 healthcare AI stocks
After Glaukos's sharp move and with the stock now only around 6% below the average analyst target, yet trading at a sizeable discount to some intrinsic value estimates, where does a reasonable view of fair value actually sit next?
Most Popular Narrative: 1.3% Undervalued
Glaukos is trading at $155.39 versus a widely followed fair value narrative of $157.50, which hinges heavily on how its pipeline and long term earnings profile evolve.
Glaukos' pipeline diversification into corneal health (Epioxa approval expected in late 2025/early 2026), novel glaucoma devices, and early-stage retinal programs positions the company to benefit from increased diagnostic rates and expanding access to ophthalmic interventions globally, providing avenues for future top-line growth and risk mitigation against single-product dependency.
Want to see what this pipeline focus assumes for revenue, margins and future earnings multiples? The narrative leans on bold growth math that is not visible in the headline fair value.
Result: Fair Value of $157.50 (ABOUT RIGHT)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Glaukos narrative still hinges on smooth reimbursement for iDose and successful execution on Epioxa, where policy shifts or launch setbacks could quickly challenge those fair value assumptions.
Find out about the key risks to this Glaukos narrative.
Another View: What Glaukos’ Sales Multiple Is Saying
The consensus narrative pegs Glaukos at roughly 1.3% undervalued, yet its P/S ratio of 16.5x tells a different story. That multiple sits well above the US Medical Equipment industry at 2.8x, peers at 4.3x, and even the fair ratio estimate of 8.3x, which points to meaningful valuation risk if sentiment changes.
For a closer look at how this pricing gap could close over time, and what that might mean for upside or downside, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Does this mix of optimism and caution around Glaukos match your own read, or does it feel stretched? Take a closer look at the data, weigh the upside against the downside, and move quickly to shape your own view with the 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond Glaukos?
Once you have a view on Glaukos, do not stop there. Widen your opportunity set by checking other stocks that fit clear, disciplined criteria using the Simply Wall Street Screener.
- Target resilience by focusing on companies that prioritise balance sheet strength through the solid balance sheet and fundamentals stocks screener (48 results)
- Spot potential value by reviewing companies that screen as priced below their assessed worth in the 49 high quality undervalued stocks
- Lock in income ideas by scanning for higher yielding companies in the 8 dividend fortresses
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com